Seelaus Asset Management LLC lowered its position in shares of Celgene Co. (NASDAQ:CELG) by 1.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,303 shares of the biopharmaceutical company’s stock after selling 400 shares during the quarter. Celgene accounts for about 3.5% of Seelaus Asset Management LLC’s investment portfolio, making the stock its 2nd biggest holding. Seelaus Asset Management LLC’s holdings in Celgene were worth $3,818,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Celgene by 4.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,014,480 shares of the biopharmaceutical company’s stock valued at $129,095,000 after buying an additional 80,990 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Celgene by 8.6% in the fourth quarter. Geode Capital Management LLC now owns 9,942,267 shares of the biopharmaceutical company’s stock valued at $636,179,000 after buying an additional 787,638 shares during the period. Capital Investment Advisors LLC acquired a new position in shares of Celgene in the first quarter valued at approximately $205,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Celgene in the first quarter valued at approximately $634,000. Finally, Altman Advisors Inc. boosted its holdings in shares of Celgene by 135.7% in the first quarter. Altman Advisors Inc. now owns 30,629 shares of the biopharmaceutical company’s stock valued at $2,890,000 after buying an additional 17,634 shares during the period. Hedge funds and other institutional investors own 74.19% of the company’s stock.

NASDAQ CELG traded up $0.15 on Tuesday, hitting $94.22. 1,407,687 shares of the stock were exchanged, compared to its average volume of 3,998,600. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.44 and a quick ratio of 3.32. The business has a fifty day simple moving average of $92.74. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $98.97. The stock has a market capitalization of $66.70 billion, a P/E ratio of 12.38, a PEG ratio of 0.44 and a beta of 1.46.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.17. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The firm had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.22 billion. During the same period in the prior year, the firm posted $2.16 earnings per share. The company’s quarterly revenue was up 15.4% compared to the same quarter last year. On average, equities analysts expect that Celgene Co. will post 9.96 EPS for the current fiscal year.

CELG has been the subject of several research analyst reports. Cowen reiterated a “hold” rating and issued a $102.00 price target on shares of Celgene in a report on Tuesday, July 30th. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 3rd. ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price for the company in a report on Tuesday, July 23rd. Finally, Mizuho restated a “buy” rating and set a $103.00 target price on shares of Celgene in a report on Wednesday, July 3rd. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $94.81.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: Blue-Chip Stocks

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.